US Edition
Roche Hy 2025 Slides: 7% Sales Growth Driven by Pharmaceutical Division
BASEL, SWITZERLAND, JUL 24 – Roche’s pharmaceuticals sales rose 10% driven by five key medicines, while four drugs for serious diseases reached final clinical trial stages, the company said.
- Roche posted better-than-expected net income of 7.8 billion Swiss francs for the first half of 2025, driven by strong pharmaceutical sales globally.
- This performance followed Roche’s April announcement to invest 50 billion dollars in the U.S. over five years amid tariff uncertainty and efforts to bypass intermediaries.
- The pharmaceuticals division grew 10 percent to 24 billion francs, thanks primarily to five key medicines treating breast cancer, asthma, and other conditions.
- CEO Thomas Schinecker highlighted that the company secured several key regulatory green lights and shared encouraging results in medical fields with significant unmet needs, while also advancing four drugs into the final stages of clinical trials.
- Roche confirmed its full-year outlook and targets mid-single-digit sales growth, while the 50 billion dollar investment aims to create over 12,000 U.S. jobs including nearly 6,500 in construction.
15 Articles
15 Articles
The Indiana Gazette Online
Pharma giant Roche sees income soar in first half
Swiss pharmaceutical giant Roche on Thursday posted better-than-expected net income for the first half of 2025 amid strong sales of asthma and breast cancer treatments.
The pharmaceutical company benefits from strong demand for medicines and confirms the outlook for the current year.
In the first half of 2025, the company increased its sales by 3.7 percent to more than 30 billion Swiss francs.
The revenues grew by 3.6%, to 30,756 million (32,935 million euros). By divisions, the pharmacy area generated 22,637 million francs (24,241 million euros) and the diagnostic area 6,959 million francs (7,452 million euros), 6% more and 3.5% less, respectively. Other concepts contributed 905 million francs (969.1 million euros).
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
